Genomma Lab Internacional, S.A.B. de C.V.
GNMLF
$1.43
$0.169913.48%
| Weiss Ratings | GNMLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Excellent | |||
| Risk Index | Fair | |||
| Risk Grade | C | |||
| Reward Grade | A- | |||
| Rating Factors | GNMLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Excellent | |||
| Efficiency Index | Excellent | |||
| Solvency Index | Excellent | |||
| Total Return Index | Good | |||
| Volatility Index | Fair | |||
| Beta / Standard Deviation | GNMLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.26 | |||
| Price History | GNMLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 12.60% | |||
| 60-Day Total Return | 12.60% | |||
| 90-Day Total Return | 26.55% | |||
| Year to Date Total Return | 12.60% | |||
| 1-Year Total Return | 75.46% | |||
| 2-Year Total Return | 70.24% | |||
| 3-Year Total Return | 57.84% | |||
| 5-Year Total Return | 31.19% | |||
| 52-Week High % Change | 0.00% | |||
| 52-Week Low % Change | 62.87% | |||
| Price | GNMLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.43 | |||
| 52-Week Low Price | $0.88 | |||
| 52-Week Low Price (Date) | Mar 15, 2024 | |||
| 52-Week High Price (Date) | Feb 06, 2025 | |||
| Valuation | GNMLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.12B | |||
| Enterprise Value | 1.32B | |||
| Price/Earnings (TTM) | 17.63 | |||
| Earnings Per Share (TTM) | 0.08 | |||
| Earnings Per Share Growth | 6.01% | |||
| Price/Earnings To Growth | 2.93 | |||
| Price/Sales (TTM) | 1.38 | |||
| Price/Book (Q) | 2.33 | |||
| Enterprise Value/Revenue (TTM) | 1.51 | |||
| Price | $1.43 | |||
| Enterprise Value/EBITDA (TTM) | 6.89 | |||
| Enterprise Value/EBIT | 7.39 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | GNMLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 942.75M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | 59.52% | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | GNMLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 52 55 5081 0000 | |||
| Address | Av. Antonio Dovalí Jaime, number 70 Mexico City, DF 01210 | |||
| Website | www.genommalab.com | |||
| Country | Mexico | |||
| Year Founded | 1996 | |||
| Profitability | GNMLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 20.41% | |||
| Profit Margin | 7.87% | |||
| Management Effectiveness | GNMLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 10.09% | |||
| Return on Equity | 12.92% | |||
| Income Statement | GNMLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 976.04M | |||
| Total Revenue (TTM) | 976.04M | |||
| Revenue Per Share | $1.04 | |||
| Gross Profit (TTM) | 615.58M | |||
| EBITDA (TTM) | 213.73M | |||
| EBIT (TTM) | 199.29M | |||
| Net Income (TTM) | 76.83M | |||
| Net Income Avl. to Common (TTM) | 76.83M | |||
| Total Revenue Growth (Q YOY) | 9.26% | |||
| Earnings Growth (Q YOY) | 55.35% | |||
| EPS Diluted (TTM) | 0.08 | |||
| EPS Diluted Growth (Q YOY) | 60.08% | |||
| Balance Sheet | GNMLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 56.67M | |||
| Cash Per Share (Q) | $0.06 | |||
| Total Current Assets (Q) | 658.73M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 579.06M | |||
| Current Ratio (Q) | 1.959 | |||
| Book Value Per Share (Q) | $0.61 | |||
| Total Assets (Q) | 1.20B | |||
| Total Current Liabilities (Q) | 336.25M | |||
| Total Debt (Q) | 352.61M | |||
| Total Liabilities (Q) | 624.41M | |||
| Total Common Equity (Q) | 579.06M | |||
| Cash Flow | GNMLF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -21.80M | |||
| Cash from Financing (TTM) | -92.62M | |||
| Net Change in Cash (TTM) | -7.60M | |||
| Levered Free Cash Flow (TTM) | 36.69M | |||
| Cash from Operations (TTM) | 102.03M | |||
